Mechanistic target of rapamycin complex 1 is involved in psoriasis and regulated by anti-TNF-α treatment

Exp Dermatol. 2017 Apr;26(4):325-327. doi: 10.1111/exd.13267. Epub 2017 Feb 2.

Authors

Anna Balato¹, Serena Lembo², Fabio Ayala³, Nicola Balato³, Giuseppina Caiazzo³, Annunziata Raimondo³, Roberta Di Caprio³, Giuseppe Monfrecola³

Affiliations

¹ Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy.
² Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", University of Salerno, Italy.
³ Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.

PMID: 27943462
DOI: 10.1111/exd.13267

No abstract available

Keywords: S6K1; mTORC1; psoriasis.

Publication types

Letter

MeSH terms

Adalimumab / pharmacology
Adalimumab / therapeutic use*
Anti-Inflammatory Agents / pharmacology
Anti-Inflammatory Agents / therapeutic use*
Case-Control Studies
Humans
Mechanistic Target of Rapamycin Complex 1 / metabolism*
Psoriasis / drug therapy
Psoriasis / metabolism*
Tumor Necrosis Factor-alpha / antagonists & inhibitors*

Substances

Anti-Inflammatory Agents
Tumor Necrosis Factor-alpha
Mechanistic Target of Rapamycin Complex 1
Adalimumab